Malignant neoplasm of breast
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
Quantification of GPC-1 level is also pivotal to breast cancer and prostate cancer's patients.
|
30202003 |
2018 |
Malignant neoplasm of breast
|
0.330 |
Biomarker
|
disease |
BEFREE |
α3(V) chains are produced in both basal-like and luminal human breast tumours, and its expression levels are tightly coupled with those of glypican-1 across breast cancer types.
|
28102194 |
2017 |
Malignant neoplasm of breast
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
Here we show that glypican-1 is strongly expressed in human breast cancers, whereas expression of glypican-1 is low in normal breast tissues.
|
11454708 |
2001 |
Malignant neoplasm of breast
|
0.330 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
Biliary Atresia
|
0.320 |
GeneticVariation
|
disease |
BEFREE |
Common variants of GPC1 gene were genetically involved in BA risk.
|
27373597 |
2016 |
Biliary Atresia
|
0.320 |
SusceptibilityMutation
|
disease |
ORPHANET |
Evidence from human and zebrafish that GPC1 is a biliary atresia susceptibility gene.
|
23336978 |
2013 |
Biliary Atresia
|
0.320 |
GeneticVariation
|
disease |
BEFREE |
We observed a statistically significant increase in deletions at 2q37.3 in patients with BA that resulted in deletion of one copy of GPC1, which encodes glypican 1, a heparan sulfate proteoglycan that regulates Hedgehog signaling and inflammation.
|
23336978 |
2013 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Treatment of xenografted mice with GPC1-GEM-NPs shows a higher tumor inhibitory effect compared with controls.
|
31414945 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Paradoxical Role of Glypican-1 in Prostate Cancer Cell and Tumor Growth.
|
31391540 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This approach is clinically relevant as a companion test to the already available diagnostic tools, since patients with GPC1-positive exosomes in peripheral blood showed decreased tumor free survival.
|
31400579 |
2019 |
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Materials & methods:</b> This work successfully designs and evaluates GPC1-targeted, gemcitabine (GEM)-loaded multifunctional gold nanocarrier for near-infrared fluorescence (NIRF)/MRI and targeted chemotherapy against pancreatic cancer <i>in vitro</i> and <i>in vivo</i>.
|
31414945 |
2019 |
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hence, enumeration of GPC1-positive EVs, solely or in conjunction with GP2, was unable to effectively distinguish between BPD and pancreatic cancer.
|
30800217 |
2019 |
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Materials & methods:</b> This work successfully designs and evaluates GPC1-targeted, gemcitabine (GEM)-loaded multifunctional gold nanocarrier for near-infrared fluorescence (NIRF)/MRI and targeted chemotherapy against pancreatic cancer <i>in vitro</i> and <i>in vivo</i>.
|
31414945 |
2019 |
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hence, enumeration of GPC1-positive EVs, solely or in conjunction with GP2, was unable to effectively distinguish between BPD and pancreatic cancer.
|
30800217 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The proportion of cases by tumor type showing staining with glypican-1 and the H-score for each tumor type were evaluated.
|
29785020 |
2018 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
However, GPC1 levels were enriched in PDAC crExos (<i>n</i> = 11), compared to the source tumors (<i>n</i> = 11; 97 ± 54 vs. 20.9 ± 12.3 pg/mL; <i>P</i> < 0.001).
|
29721179 |
2018 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
On immunohistochemical staining, high expression levels of GPC1 were detected in about 50% of uterine cervical cancer tissues and also in a tumor that had relapsed after chemoradiotherapy.
|
29055044 |
2018 |
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
ORI-GPC1-NP is a promising theranostic platform for the simultaneous diagnosis and effective treatment of pancreatic cancer.
|
30425490 |
2018 |
Pancreatic carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
GPC-1 is a type of cell surface heparan sulfate proteoglycan, which is often highly expressed in PC.
|
29750031 |
2018 |
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Glypican-1 is enriched in circulating-exosomes in pancreatic cancer and correlates with tumor burden.
|
29721179 |
2018 |
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prognostic value of glypican-1 for patients with advanced pancreatic cancer following regional intra-arterial chemotherapy.
|
29963198 |
2018 |
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Glypican-1 (GPC-1) has been recognized as biomarker of pancreatic cancer.
|
30202003 |
2018 |
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prognostic value of glypican-1 for patients with advanced pancreatic cancer following regional intra-arterial chemotherapy.
|
29963198 |
2018 |
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
ORI-GPC1-NP is a promising theranostic platform for the simultaneous diagnosis and effective treatment of pancreatic cancer.
|
30425490 |
2018 |
Malignant neoplasm of pancreas
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
GPC-1 is a type of cell surface heparan sulfate proteoglycan, which is often highly expressed in PC.
|
29750031 |
2018 |